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is overlap in the criteria to qualify for funding. Many countries consider drugs for 
additional funding when a drug can be used in more than one indication and can-
not be grouped to a specific DRG. Other criteria identified relate to, for example, 
drug prices and indications. Some countries grant additional reimbursement for 
drugs prior to assessment by a national reimbursement process, while others only 
grant additional reimbursement after the drug has been available for a certain 
period of time and funding decisions are based on historical data. In most countries, 
additional reimbursement is considered annually. Hospitals and expert groups can 
suggest additional reimbursement for expensive drugs to the responsible author-
ity. ConClusions: Many countries have adapted to the need for additional funding 
for expensive drugs, and have established systems to grant this funding to hospitals. 
There are differences in criteria to qualify for, and timelines for receiving, additional 
funding after drugs are launched.
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objeCtives: Initiatives aimed at improving both the quality and efficiency of United 
States health care are commonly grouped under the broad category of “pay-for-
performance” (P4P) programs. Typically these programs award bonuses to providers 
that attain pre-determined quality and cost goals, but may also impose financial 
penalties on those that fail to meet those goals. Fueled by the Affordable Care Act, 
P4P programs have recently expanded significantly within the public sector and 
are expected to grow. This project was designed to review Medicare P4P cost meas-
ures, discuss the implications for provider prescribing patterns, and recommend 
possible alternatives. Methods: Two P4P programs, both well known under the 
health reform law and having potential to impact a large portion of the Medicare 
population, were evaluated: 1) Accountable Care Organizations (ACO), and 2) the 
Physician Value Based Payment Modifier (VBPM). Each program’s cost measure 
components and calculation methodologies were isolated, described and evalu-
ated for the potential to influence prescribing patterns. Results: Cost measures 
for the ACO and VBPM programs are based on payments made under Medicare Part 
A (Hospital Insurance) and Medicare Part B (Supplemental Insurance) but do not 
include Medicare Part D (Prescription Drug Benefit) costs. Whether performance 
is measured against the provider’s historic costs, or compared to national bench-
marks, only Medicare Parts A and B costs are included. ConClusions: Medicare 
Part D costs are not included in the cost measure calculation, thereby eliminating 
prescription drug expense from the performance rating. This methodology may 
encourage providers to shift Part B drug costs to Part D, thus limiting patient access 
to therapies that may only be covered under Medicare Part B.
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objeCtives: To provide an up-to-date description and comparative analysis of pric-
ing and reimbursement policies in South-Eastern Europe (SEE), and to identify fac-
tors influencing reimbursement decisions. Methods: Payers and decision makers 
in Slovenia, Croatia, Romania and Bulgaria were interviewed by questionnaire. An 
additional literature survey covered country-specific legislation and publications 
(PubMed 2009–2014), and relevant documents from web sources including national 
hospital insurance funds, drug agencies, ministries of health, Eurostat, pharmacoeco-
nomic and outcomes research conference proceedings, the Organisation for Economic 
Co-operation and Development, and Business Monitor International. Results: The 
four countries spent 5.1%–8.8% of gross domestic product on health in 2012. Price 
controls are commonly used, applied via negotiation with marketing authorisation 
holders or indirectly through the application of copayments. Key policies are based 
on international and internal reference pricing. Bulgaria, Romania and Slovenia 
base pricing on the lowest manufacturing or retail price, while Croatia uses average 
pricing. Reimbursement requires demonstration of clinical and economical benefits 
over current standard therapy. When the importance of benefits are recognised and 
recommendations from reference health technology assessment authorities in 
Europe are published, budget impact analyses focusing on key drivers such as target 
population and price are applied. Cost containment mechanisms are also applied, 
including net price negotiation, rationing, decision postponement, payback, claw-
back and risk sharing, with the aim of protecting overall budgets. Legislative changes 
to pricing and reimbursement systems are very common. Out-of-pocket expenses 
in Romania and Bulgaria are among the highest in Europe, while the reimbursed: 
retail price difference is largely covered by supplementary insurance in Slovenia and 
Croatia. ConClusions: The middle/lower income SEE countries use reference pric-
ing, and have some of the lowest prices in the European Union. Reimbursement of 
innovative drugs is restricted, there are downward trends in pricing, and risk-sharing 
agreements based on outcomes are finance-driven.
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objeCtives: To gain a better understanding of the pricing and reimbursement pro-
cesses and evidence requirements at national, regional, and local levels with regards 
to a biologic obtaining a license in a second indication in the UK, France, Italy, and 
Spain. Methods: In countries with a largely national system (UK, France), five 
telephone interviews were conducted; as Spain and Italy also have local and regional 
systems, 17 and 18 interviews, respectively, were conducted. Stakeholders included 
payer-advising clinicians, hospital administrators and pharmacists, regional pay-
ers, and local payers. Results: In the UK and France, pricing and reimbursement 
is agreed at a national level, with few restrictions at regional and local levels. In the 
UK, NHS England is likely to be responsible for funding of new biologics and relies 
on guidance from NICE before adopting a product in a new indication; therefore, 
demonstrating cost-effectiveness is key. In France, the ASMR issued by the transpar-
ency commission is important; funding usually is through the groupe homogéne 
de séjour. In addition to demonstrating clinical benefits, pharmacoeconomic stud-
ies may be required for high-cost drugs. In contrast, in Italy, although AIFA needs 
to approve a new product on a national level, subsequent requirements vary by 
region and sometimes specific location. Similarly, in Spain, once approved nation-
ally, regions develop their own recommendations, and local decisions are made by 
hospital formularies. Evidence requirements in Italy and Spain vary at national, 
regional, and local levels. ConClusions: A biologic obtaining a license in a new 
indication must undergo the same procedure as a new product. The process and 
restrictions for biologics may be stricter than for other medications due to the 
perceived high cost. The level of national, regional, and local requirements and 
restrictions varies; it is important that appropriate evidence is submitted to deci-
sion makers at each level.
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objeCtives: Medical devices, together with pharmacotherapy are supportive treat-
ment of many acute and chronic diseases. The place of their dispensing and direct 
sale is the dispenser of medical devices. Many medical devices are reimbursed from 
public health insurance funds entirely, for others, particularly advanced functional 
types of medical devices, there must the patient participate on the price or he can 
buy them according own decision. Methods:  The target of the work was to analyse 
the data from paid databases of Slovak authority National Center for Health 
Information that collects the outputs of provided health care services. The most 
recent data were from 1.1. - 30.9.2014. Results: Referring to the Center for Health 
Information until 30.9.2013 there were 226 registered establishments that sell medical 
devices. Their specialization were dispenser of medical devices (n= 163), dispenser of 
orthopedic devices (n= 48) and dispenser of audioprotetic devices (n= 15). Expenditure 
of reimbursed medical devices from public health insurance funds amounted 
n-monthly packaging= 8,8mil and n-monthly value= 12,7 mil € . The highest shares had the 
group medical devices for incontinence and urinary retention (n-packages= 7,7 mil, 
n-packages%= 86.9, n-values= 3,9 mil € , n-value%= 30.9), the group plasters and bandag-
ing materials (n-packages= 0,5 mil, n-packages%= 6.1, n-values= 2,6mil € , n-value%= 10.2) and 
medical devices for ostomates (n-packages= 0,4 mil, n-packages%= 4.6, n-values= 1,6 mil € , 
n-value%= 8.1). direct sale of medical devices to the patients reached n-monthly packaging= 
 0, 9 mil and n-monthly value= 1,1mil € . The highest shares had the group medical devices 
for incontinence and urinary retention (n-packages= 5,7 mil, n-packages%= 50.3, n-values= 
2, 6 mil € , n-value%= 26.2), the group plasters and bandaging materials (n-packages= 3,5 
mil, n-packages%= 30.9, n-values= 2,0 mil € , n-value%= 20.4) and medical devices for 
diabetics (n-packages= 0,5 mil, n-packages%= 4.5, n-values= 0,7 mil € , n-value%= 7.3).  
ConClusions: Medical devices are reimbursed frompublic health insurance funds 
or paid by patient and their proportion constitutes 7: 1 in packages and 11: 1 in Eur.
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objeCtives: Troika’s measures to support Greece’s financial recovery have tar-
geted all sectors of economy including health care. Since 2012, policy reforms have 
changed the way health care is funded, managed and delivered, and how pharma-
ceuticals are priced, accessed and reimbursed. This study examines the changes 
to the Greek system and tries to understand the wider possible impact on global 
pricing and access strategies. Methods: To better understand the recent reforms 
we conducted a literature review of public domain sources, including the Greek 
Government Gazette, PubMed and other websites. Searches were conducted in 
English and Greek-language, and materials were translated into English. From our 
findings a road map diagram was developed, and this was validated by interviews 
with health policy experts. Results: Part of troika’s campaign to reduce public 
spending has seen the Greek government focus on pharmaceutical markets and 
introduce policies to contain costs. The drug budget for 2014 has been cut to 2 
billion euros, a billion lower than 2013. Considerable price cuts have been agreed 
on both novel and generic agents on top of clawbacks and rebates for high cost 
drugs. Prescribing is controlled through electronic prescription and physician budget 
caps. Introduction of price-volume agreements and risk sharing schemes are being 
considered, however the infrastructure to support implementation is still under 
development. Demonstrating value by health economics and outcomes research 
can still help manufacturers to achieve premiums. ConClusions: With a small 
population and an ever-decreasing expenditure on health care, it is tempting to 
overlook Greece when developing a product launch strategy. However, with Greek 
drug prices being referenced by several EU and non-EU countries, ignoring Greece 
may no longer be an option, especially when considering the indirect effect on the 
big EU5 prices. Understanding the reforms and assessing the impact on launch 
sequencing will be key in developing optimal pricing strategies.
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